What changed
Direct answer
What you need to know
Evidence strength: StrongA comparison is only true on the day it was checked, and this page is where we record the days it stopped being true. 13 dated entries covering price changes, terms changes, litigation, regulatory action, and the times our own check of a provider failed. Every line carries a source you can open, and each says whether it comes from the public record, a provider’s own page, or something our sweep observed.
Key takeaways
- 2 announced changes have not taken effect yet — those are the rows worth acting on.
- Where we got something wrong ourselves, it is logged here and in corrections.
- Allegations are recorded as allegations, and dismissals are recorded too.
- Directory records are re-read on a schedule; the next sweep is due 2026-09-10.
Important limitation: This is not exhaustive and it is not investigative. It records what we have found in the public record or on a provider’s own site. A change nobody published, and our sweeps did not catch, will not be here.
Next action: The current terms for each provider are in the directory, and what a provider must satisfy to be listed is in the listing standard.
General education, not medical advice. Nothing here is an allegation of wrongdoing by anyone; where a claim has been made, it is attributed to whoever made it.
Why this is not a watchdog page
This site intends to earn flat referral fees from providers listed in its directory. A publication funded by the companies it polices is not a watchdog, whatever it calls itself, and a flat fee does not fix that — it protects against selling a better ranking, not against choosing softer targets or pulling a punch.
So this page does the part that survives the conflict. It records events that already exist in the public record or in a provider’s own published terms, and attributes every claim to whoever made it. It does not investigate, allege, or characterise. That is real work and it is genuinely useful, and it is also less than a watchdog does. Saying so is cheaper than pretending otherwise and being caught at it.
Announced, not yet in effect
These are the entries a reader can still act on, which is why they sit above the rest rather than in date order with everything else.
Novo Nordisk (NovoCare self-pay) — takes effect 2026-08-31
NovoCare's self-pay page states that the $149/month tier covering the 1.5 mg and 4 mg Wegovy tablet doses rises to $199/month for the 4 mg dose after 31 August 2026, and that its pricing will be updated after that date.
What it means. $149 is the lowest published price for any FDA-approved product in this class, and it is the figure most “cheapest GLP-1” comparisons quote. Anyone relying on it after 31 August should re-check the dose it applies to.
Provider's own page · NovoCare (Novo Nordisk) self-pay pricing
Novo Nordisk (US list price) — takes effect 2027-01-01
Novo Nordisk announced a reduction in the US list price of Wegovy, Ozempic and Rybelsus to $675, effective 1 January 2027, stating that the change does not affect direct-to-patient self-pay prices.
What it means. List price is what insurers and pharmacies negotiate from, not what a self-paying patient is charged. The announcement is widely reported as a price cut; for a cash payer it may change nothing, and the company says so.
Public record · Novo Nordisk announcement
The full log
Newest first. 13 entries as of 2026-08-21.
| Date | Subject | What happened, and what it means | Basis |
|---|---|---|---|
| 2026-08-21Availability | Mochi Health | Mochi Health now lists brand-name products alongside its compounded ones, each with its own starting price: Ozempic from $199, Wegovy and Zepbound from $299, Foundayo from $149, Mounjaro from $499. It also lists compounded oral semaglutide from $137 and compounded orforglipron from $104. Our record described it as compounded-only, verified 11 August.It changes which group the provider sits in on our directory, which is organised by access model rather than by price. A reader filtering for brand-name medication would not have been shown Mochi at all. | Provider's own pagejoinmochi.com |
| 2026-08-21Pricing | Mochi Health | Compounded semaglutide is now advertised from $60/month and compounded tirzepatide from $90/month, each presented as a reduction from a higher figure ($99 and $199 respectively). Our record carried $59 and $71 from 11 August. We are recording what the page says today rather than reconciling it with what it said before, because we cannot see what happened in between.With the $79 membership added, the semaglutide total moves from $138 to $139 a month and the tirzepatide total is $169 — the cheapest compounded tirzepatide total we can derive from published figures. | Observed by our sweepjoinmochi.com |
| 2026-08-21Our own check | Mochi Health | Our cost model carried only Mochi's compounded semaglutide option, never its tirzepatide one, although the provider has advertised both throughout. This was our omission, not a change at the provider.The tirzepatide cost page counted the compounded suppliers it lists from that model, so it reported two where there are three — and the one missing was the cheapest of them. | Observed by our sweepjoinmochi.com |
| 2026-08-13Pricing | Novo Nordisk (NovoCare self-pay) | NovoCare's self-pay page states that the $149/month tier covering the 1.5 mg and 4 mg Wegovy tablet doses rises to $199/month for the 4 mg dose after 31 August 2026, and that its pricing will be updated after that date.$149 is the lowest published price for any FDA-approved product in this class, and it is the figure most “cheapest GLP-1” comparisons quote. Anyone relying on it after 31 August should re-check the dose it applies to. | Provider's own pageNovoCare (Novo Nordisk) self-pay pricing |
| 2026-08-11Our own check | Calibrate | Our sweep found that calibrate.com, which this directory had been linking to, is not the provider's site — it resolves to an unrelated parked page of cryptocurrency and NFT links. The provider's site is joincalibrate.com.Anyone who followed our link before 11 August 2026 landed somewhere with no connection to the company we were describing. The link is corrected and the error is in our corrections log. | Observed by our sweepOur provider sweep, 11 August 2026 |
| 2026-08-11Pricing | Alloy | Alloy stopped publishing the brand-name medication prices this site had previously recorded. The figures are no longer readable on a public page.We removed the route rather than carry a stale figure. A provider withdrawing published pricing is itself worth knowing when you are comparing on price. | Observed by our sweepOur provider sweep, 11 August 2026 |
| 2026-08-11Pricing | Sesame | Success by Sesame is published at $249 per month with medication included. This site had previously recorded an optional subscription from $59 per month.We cannot establish whether the price moved or whether we mis-read the tiers originally, and we are not going to guess in the flattering direction. Either way the earlier figure was about half the real one. | Observed by our sweepOur provider sweep, 11 August 2026 |
| 2026-06-26Regulatory | US Food and Drug Administration | The FDA extended the public comment period on its proposal to leave semaglutide, tirzepatide and liraglutide off the 503B bulk drug substances list, from 30 June to 30 July 2026.The 503B list governs what outsourcing facilities may compound at scale. The outcome affects whether the compounded route in this directory continues to exist. | Public recordFederal Register notice |
| 2026-03-01Terms | Hims & Hers | A March 2026 settlement with Novo Nordisk ended Hims & Hers' practice of offering compounded semaglutide to new patients.The compounded route people associate with this provider is no longer open to new patients, so older comparisons describing it are out of date. | Public recordHims & Hers newsroom |
| 2026-02-24Pricing | Novo Nordisk (US list price) | Novo Nordisk announced a reduction in the US list price of Wegovy, Ozempic and Rybelsus to $675, effective 1 January 2027, stating that the change does not affect direct-to-patient self-pay prices.List price is what insurers and pharmacies negotiate from, not what a self-paying patient is charged. The announcement is widely reported as a price cut; for a cash payer it may change nothing, and the company says so. | Public recordNovo Nordisk announcement |
| 2025-09-01Litigation | Willow Health | A federal judge dismissed Eli Lilly's April 2025 claim against Willow Health over compounded tirzepatide marketing.Recorded because the filing was recorded. A directory that logs the accusation and not the dismissal is not keeping a record, it is keeping a grudge. | Public recordLengea Law, legal industry coverage |
| 2025-04-01Litigation | Mochi Health | Named as a defendant in a federal lawsuit filed by Eli Lilly in April 2025 alleging deceptive marketing of compounded tirzepatide and semaglutide products, including undisclosed additives.An allegation is not a finding. It is on the record, it concerns the compounded products this provider sells, and a reader comparing compounded options should know the case exists. | Public recordEli Lilly litigation coverage (Reuters) |
| 2025-01-01Regulatory | Willow Health | Following a challenge from Novo Nordisk, the BBB National Programs' National Advertising Division recommended that Willow Health modify or discontinue certain health-related claims in its marketing.NAD is self-regulatory rather than a government regulator, and its recommendations are not binding. It is still an independent body reviewing claims a reader would otherwise take at face value. | Public recordNational Advertising Division referral coverage |
A directory that logs the accusation and not the dismissal is not keeping a record. It is keeping a grudge.
Three of these are our own mistakes
The Calibrate link, the Alloy prices and the Sesame figure are entries about us, not about them. They are here for the same reason they are in the corrections log: a record that only contains other people’s changes is a marketing page. The last full directory sweep ran 2026-08-11 and the next is due 2026-09-10.
The prices themselves, over time
This log records events. The figures those events moved are kept separately as a dated series, because “what did this cost in August” is a different question from “what happened in August” — every reading we hold, with the date and source attached to each, including the changes sellers have announced but not yet made.
Where these entries show up in a price
A log is only useful if it changes a decision, and most of these entries change one of two numbers. The litigation entries concentrate on one molecule — the compounded tirzepatide market these cases concern is smaller than the semaglutide one, and the log is where the dates and the outcomes sit rather than in a footnote under a price. The price-change entries mostly land on the other, where an announced rise to the cheapest approved product in the class has a date attached that has not passed yet.
Tell us what we have missed
If a provider’s terms have changed and it is not here, send it to corrections@glp1.healthcare with a link to where it is published. We will not log anything we cannot source.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.